The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/IIa study to evaluate the tolerability, safety, pharmacokinetics and efficacy of eciruciclib (BPI-1178) alone in advanced solid tumors and in combination with endocrine therapy for advanced or recurrent HR+/HER2- breast cancer.
 
Yiqun Du
No Relationships to Disclose
 
Jiong Wu
No Relationships to Disclose
 
ChangLu Hu
No Relationships to Disclose
 
Wenyan Chen
No Relationships to Disclose
 
Min Yan
No Relationships to Disclose
 
Wei Li
No Relationships to Disclose
 
Yongsheng Li
No Relationships to Disclose
 
Yuee Teng
No Relationships to Disclose
 
Huiping Li
No Relationships to Disclose
 
Tao Huang
No Relationships to Disclose
 
Yongkui Lu
No Relationships to Disclose
 
Don Zhang
Employment - Beta Pharma Inc.
Leadership - Beta Pharma Inc.
Stock and Other Ownership Interests - Beta Pharma Inc.
Patents, Royalties, Other Intellectual Property - Beta Pharma Inc.
 
Jirong Peng
Employment - Beta Pharma Inc.
 
Feng Gao
Employment - Beta Pharma Inc.
 
Tingting Wang
Employment - Beta Pharma (shanghai) co., Ltd.
 
WenXuan Zhang
Employment - Beta Pharma (shanghai) co., Ltd.
 
Jian Zhang
No Relationships to Disclose